Amylon Therapeutics B.V.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Amylon Therapeutics B.V.
Revealed: In Vivo’s list of 30 Rising Leaders across the biopharma, medtech and health technology sectors. Find out who made the cut.
Third-quarter biopharma financing, which totaled $12.5 billion, was dominated by follow-on public offerings, which represented virtually half the value. Acquisition activity was headlined by a major move by Gilead in the CART market. Five alliances were signed worth over $1 billion, led by a partnership between two key players, Merck & Co. and AstraZeneca.
Pfizer-backed SpringWorks, ProQR spin-out Amylon and Landos, the first firm out of accelerator Xontogeny, gain their own financing. Other venture rounds support Autolus, Grid Therapeutics, Excision and more.
ProQR spinout Amylon gets started by licensing four central nervous system disorder candidates from its parent, while start-up Eyevance gets US rights to Nicox’s Zerviate.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries